The quantity of administered factor VIII concentrates has not seemed to correlate with changes in
Immunological abnormalities have recently been found in otherwise healthy patients with severe haemophilia A,18 and include lymphopenia, a relative and absolute reduction of T helper lymphocytes, and a relative increase of T suppressor lymphocytes giving an inversed T helper:T suppressor ratio (T4:T8). Lyophilised factor VIII concentrates have been implicated as the cause of these abnormalities rather than cryoprecipitate,2 3 although immunological studies have not always been normal in haemophiliacs treated with cryoprecipitate.9 11
The quantity of administered factor VIII concentrates has not seemed to correlate with changes in T cell subpopulations,2 3 6 12 although two reports have related low T4:T8 ratios with higher exposure to factor VIII concentrate. 13 14 Patients treated with prothrombin complex concentrates have generally had similar immunological findings to controls, 6 9 13 although this has not been a consistent finding.14 Thrombocytopenia, of an immune type in some cases,15 has been reported in patients with haemophilia A.6 16 17 A relation, however, between transfused factor VIII concentrate and thrombocytopenia has not been established.
Haemophilic boys and adolescents have been reported with immunological abnormalities similar to those described in adult haemophiliacs and patients with the acquired immune deficiency syndrome (AIDS). 4 Prospective longitudinal study of haemophiliacs is clearly needed to assess both the importance of these abnormalities and the degree of risk of developing AIDS. We have initiated such a study of haemophilic boys and children with other bleeding disorders. The type and quantity of blood products have been evaluated in relation to immunological and haematological abnormalities.
Patients and methods
Patients. All patients studied attend the Haemophilia Unit, Children's Hospital, Birmingham, and were healthy at the time of the study.
Thirty seven boys (mean age 8-1 years) had severe haemophilia A (presenting factor VIII:C less than 2%) and all had received both commercial (Armour Intermediate Purity Factor VIII) and NHS factor VIII concentrates. Among these patients there were four high and two low responder 530 inhibitor patients. Three of the high responders had also at times received Factor Eight Inhibitor Bypassing Activity product (FEIBA, Immuno, Austria) when treatment with factor VIII concentrate had failed. Complete treatment records are available for these children. Mean factor VIII consumption by severe haemophiliacs including the inhibitor patients was 23 000 U/year. For the purpose of analysis, however, we have divided patients with severe haemophilia A into high treatment (mean treatment greater than 25 000 U/year), and low treatment (less than 25 000 U/year) groups.
Seventeen boys (mean age 9-7 years) with mild/ moderate haemophilia A (presenting factor VIII:C greater than 2%) were studied, 11 of whom had received both factor VIII concentrate and cryoprecipitate, and six cryoprecipitate only. One of these boys had become a high responder inhibitor patient and this made his haemophilia more severe. He required frequent treatment (mean yearly usage of 30 000 U factor VIII) like most of the other inhibitor and severe haemophiliac patients. Treatment of inhibitor patients was mainly with high doses of factor VIII concentrate.
Nine patients with von Willebrand's disease and six patients with combined factors V and VIII deficiency (mean age 11 years) had received only cryoprecipitate and were considered as a separate patient/treatment group. Some had received treatment infrequently.
Seven boys with severe haemophilia B (factor IX less than 2%) and two boys with severe factor X deficiency (factor X less than 2%) were studied (mean age 7*5 years). All had been treated with NHS prothrombin complex concentrates (mean consumption 18 000 U/year), and were considered as an additional patient/treatment group. One of the boys with haemophilia B is a high responder inhibitor patient.
Controls. Twenty five children without haemostatic problems formed the control group. All were well at the time, and apart from six having elective surgery, the others were normal children being investigated for small stature which had been shown to be constitutional, that is they are short, otherwise normal children.
Statistical analysis. Patient and control groups were analysed statistically using the Mann-Whitney test, Spearman's rank correlation coefficient, and x2 where appropriate.
Methods. Total white cell counts were determined with a Coulter S counter on venous blood anticoagulated with ethylenediamine tetra-acetic acid, and differential white cell counts were done on blood films stained with Wright's stain. Platelet counts were determined using a TOA platelet counter (PL100). Automated immunoturbidimetric determination of immunoglobulins by centrifugal analysis was performed. 18 Liver function tests were performed by standard biochemical methods. Mononuclear cells were isolated on 'Ficoll-Hypaque' and T lymphocyte subsets defined using monoclonal antibodies T4 and T8 by an indirect immunofluorecence, according to the manufacturer's instructions (Coulter Electronics). Helper lymphocytes would be included in those identified by T4 and suppressor lymphocytes with those identified by T8. Results were finally expressed as T4:T8 ratios.
Results
Values for total white cell, lymphocyte, and platelet counts, and T4:T8 ratios for each patient group are shown in the Table. Boys with severe haemophilia A in the higher treatment group had significantly lower total white cell counts (P<0.02), lymphocyte counts Factor VIII U (x103) Two of 17 patients with mild haemophilia A had inversed T4:T8 ratios, one associated with hypergammaglobulinaemia and thrombocytopenia. Both had recently received factor VIII concentrates. Patients treated exclusively with cryoprecipitate in this group and in other groups (von Willebrand's disease and combined factors V and VIII deficiency) had normal results, apart from two patients with von Willebrand's disease who had only hypergammaglobulinaemia. They had both recently received large quantities of cryoprecipitate.
One patient with haemophilia B, in the group treated with prothrombin complex concentrate, had hypergammaglobulinaemia only. All other haematological and immunological results in this group were normal. Three of nine of these patients had raised transaminases.
Four of five high responders and the two low responder factor VIII inhibitor patients with Haematological and immunological abnormalities have been described in asymptomatic patients with haemophilia A. These include inversed T4:T8 ratios,2 3 lymphopenia and thrombocytopenia, 6 and hypergammaglobulinaemia. Among the boys with severe haemophilia A in this study, we have found similar findings. In addition, however, we have shown a significant inverse correlation between the quantity of factor VIII concentrate administered and T4:T8 ratios, total white cell, lymphocyte, and platelet counts. Significant differences in these immunological and haematological values were found between the higher treatment group (mean treatment greater than 25 000 U/year) and the lower treatment group (less than 25 000 U/year). Hypergammaglobulinaemia was significantly associated with low T4:T8 ratios, low platelets, and the higher treatment group. In these patients with severe haemophilia A, increasing abnormalities are associated with increasing usage of factor VIII concentrates. As all these patients had received both NHS and commercial factor VIII, we were unable to ascribe observed abnormalities to type of concentrate.
The pathogenesis of these immunological abnormalities is not known. A transmissible agent, possibly viral, in factor VIII concentrates has been suggested. '9 The recipients of factor concentrates are known to be at increased risk from a large number of viral infections, including Epstein-Barr virus, cytomegalovirus,20 hepatitis B and non-A non-B hepatitis,21 and serum parvo-like virus.22 Alteration of lymphocyte populations is a known sequelae of infection with the first two of these viruses, 24 25 and serum parvo-like virus has been suggested as a possible cause of the altered T cell populations seen in haemophiliacs, as it is present in factor VIII concentrate22 and animal parvoviruses are known to infect lymphocytes.26 Increasing usage of factor VIII concentrate seems to increase the risk of exposure to the lymphadenopathy associated virus or human T lymphotropic virus type III.23 As the former is lymphotropic, it would be expected to have effects on cellular immunity, including lymphocyte popula- Hypergammaglobulinaemia is a recognised finding in some patients with asymptomatic severe haemophilia A. 4 
